CD209 and rheumatoid arthritis: Treatment with Tofacitinib resulted in a significant decrease in the frequency of CD209/CD14+ DC in both RA and PsA patients, suggesting that the JAK/STAT pathway is involved in the development of CD209/CD14+ DC subset, which is in agreement with our previous studies (23).